Health
Health is a sector shaped both by global trends, technologies and innovation, and by local market conditions, demographics and regulations.
Investment and consolidation in Asia are driven by:
- The growth in disposable income, rapidly changing and diversely different demographics;
- Geographically and physiologically distinct characteristics;
- The evolution of government-sponsored health systems; and
- The emergence of true innovators in medical and life science technologies within the region
Access to these growth markets by global participants, and the thirst of regional actors for M&A in both directions between Asia and the West.
Our global Health team serves our corporate, financial sponsor and entrepreneurial clients by combining our deep local capability and insights across Asia with our global perspectives and transactional track record. Our experience spans healthcare services, medical technology, pharma and biotech, outsourced pharma services (CRO, CDMO), consumer health, and animal & plant life sciences.

Andrew Huntley
Managing Partner, Head of Healthcare

Sanjay Singh
Partner, Head of India, Co-Head of Asia Healthcare
Received investment from TA Associates
2023
Acquired Shenzhen Wikkon
2022
Divested B Medical Systems to Azenta
2022
Agreed to divest East Syracuse, New York facility to LOTTE Corporation
2022
Sold minority stake to Quadria Capital
2022
Acquired by Novo Holdings
2022
Investment from The Riverside Company
2021
Acquired by MicroPort
2021
Divested majority stake in OPV Pharmaceuticals to RV Healthcare
2021
Acquired by Mindray
2021
Divested majority stake to DCP Capital
2021
Agreed to divest Couvet, Switzerland facility to WuXi AppTec
2021
Raised Series B round from ABC World Asia
2021
Divested Neoss to CareCapital
2020
Divested Escientia Life Sciences to Deccan Fine Chemicals
2020
Divested significant stake in Kehua Bio-Engineering to Gree Real Estate
2020
Divested LAP Laser to IK Investment Partners
2019
Divested majority stake to The Longreach Group
2019
Divested plant health business in Japan to Nisso
2018
Divested The Ritedose Corporation to AGIC and Humanwell
2017
Majority recapitalized by Galen Partners
2017
Divested CMC Biologics to Asahi Glass
2017
Acquired Graphic Controls, USA
2016
Divested to a Japanese chemicals & life science company
2016